-
Mashup Score: 123ctDNA Assays: Exploring Their Clinical Use in Oncology Care - 11 day(s) ago
ctDNA assays are quickly finding their way into the clinic. These assays have a potential role to play in all phases of the cancer continuum because they answer various clinical questions (Figure 1). Their use is moving up to earlier-stage settings from their initial development and approval for patients with metastatic cancer. As these agents enter more prominent clinical use, it is vital for clinicians to understand that there are different kinds of ctDNA assays.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 89Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer - 14 day(s) ago
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma - PubMed - 21 day(s) ago
Early FDG PET/CT can identify metabolic changes in melanoma metastases that are potentially predictive of response to pembrolizumab and significantly correlated with PFS.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 102Ongoing Research Shows Promising Results for Neoadjuvant Treatment for Colorectal Cancer - Advances in Gastroenterology & Oncology | NewYork-Presbyterian - 1 month(s) ago
A phase 2 trial led by a NewYork-Presbyterian/Weill Cornell Medicine oncologist reveals the efficacy of neoadjuvant botensilimab plus balstilimab in patients with colorectal cancer.
Source: www.nyp.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44The Promise of Liquid Biopsies | Cancer Today - 1 month(s) ago
Blood tests that detect traces of cancer cells and tumor DNA help find residual disease after treatment is completed.
Source: www.cancertodaymag.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27[Vídeo] EP37 - ctDNA in Colorectal Cancer - Beyond Early Detection - 1 month(s) ago
Listen to this episode from The Late Night Oncology Show on Spotify. [Episódio em Inglês] Para fechar o mês de conscientização dos tumores colorretais, recebemos Dr. Pashtoon Kasi, oncologista clínico com foco em tumores gastrointestinais, professor na Weill Cornell Medicine e autor do estudo BESPOKE CRC, para discutir aspectos relacionados a biópsia líquida em câncer colorretal, incluindo a importância na detecção precoce, determinação de tratamento adjuvante e monitoramento do tratamento no cenário metastático.
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet-
Was a delight to be on the @LateNightOnc🎙️🇧🇷 in the company of some wonderful physicians & scientists discussing #ctDNA🧬🩸. 👇🏾Episode available on Spotify. 💡More now than ever it is important to understand the limitations & best use case/scenarios. https://t.co/vMpl6O6o1m https://t.co/iJi6kNzSAY https://t.co/wZSBT6Dvvn
-
-
Mashup Score: 88Ongoing Research Shows Promising Results for Neoadjuvant Treatment for Colorectal Cancer - Advances in Gastroenterology & Oncology | NewYork-Presbyterian - 1 month(s) ago
A phase 2 trial led by a NewYork-Presbyterian/Weill Cornell Medicine oncologist reveals the efficacy of neoadjuvant botensilimab plus balstilimab in patients with colorectal cancer.
Source: www.nyp.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 140Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer - 2 month(s) ago
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence - 2 month(s) ago
Objective We evaluated whether people who had not completed a faecal immunochemical test (FIT) for colorectal cancer (CRC) screening would complete a blood-based testing option if offered one during health encounters. Blood-based screening tests for CRC could add to the total number of people screened for CRC by providing another testing alternative. Design Study participants were patients aged 45–75 years at a large, integrated health system who were offered but did not complete an FIT in the prior 3–9 months and were scheduled for a clinical encounter. Individuals were randomised (1:1) to be offered a commercially available CRC blood test (Shield, Guardant Health) versus usual care. We compared 3-month CRC screening proportions in the two groups. Results We randomised 2026 patients; 2004 remained eligible following postrandomisation exclusions (1003 to usual care and 1001 to blood draw offer; mean age: 60, 62% female, 80% non-Hispanic white). Of the 1001 allocated to the blood test g
Source: gut.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 49Attacking Colorectal Cancer From the Roots Up - 2 month(s) ago
Giving two immunotherapy drugs before surgery to remove colorectal cancer shows highly promising results
Source: www.scientificamerican.comCategories: General Medicine News, Hem/OncsTweet
#ctDNA🧬can be broadly divided into tumor-informed🔬🆚tumor-naive🩸 platforms. Different lenses🔎of looking at the cancer through a blood draw. Depending on the clinical question & tumor type, different types available. #ASCODailyNews @ASCO @DrawImpacts https://t.co/o5LnECXNn0 https://t.co/Ct5kVwkh7G